Next Article in Journal
Ethical Issues Associated with Medical Tourism in Africa
Previous Article in Journal
Filling the Gap in CNS Drug Development: Evaluation of the Role of Drug Repurposing
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 5
Issue 1
10.1080/20016689.2017.1307315
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Supply-Side and Demand-Side Policies for Biosimilars: An Overview in 10 European Member States

by
Cécile Rémuzat
1,*,
Anna Kapuśniak
2,
Aleksandra Caban
2,
Dan Ionescu
3,
Guerric Radière
3,
Cyril Mendoza
3 and
Mondher Toumi
4
1
Pricing and Market Access Department, Creativ-Ceutical, Paris, France
2
Pricing and Market Access Department, Creativ-Ceutical, Krakow, Poland
3
Global Pricing and Market Access Biopharmaceuticals Department, Sandoz International GmbH, Holzkirchen, Germany
4
Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2017, 5(1), 1307315; https://doi.org/10.1080/20016689.2017.1307315
Submission received: 22 December 2016 / Revised: 1 January 2017 / Accepted: 8 March 2017 / Published: 28 April 2017

Abstract

Objective: This study aimed to provide an overview of biosimilar policies in 10 EU MSs. Methods: Ten EU MS pharmaceutical markets (Belgium, France, Germany, Greece, Hungary, Italy, Poland, Spain, Sweden, and the UK) were selected. A comprehensive literature review was performed to identify supply-side and demand-side policies in place in the selected countries. Results: Supply-side policies for biosimilars commonly include price linkage, price re-evaluation, and tendering; the use of internal or external reference pricing varies between countries; health technology assessment is conducted in six countries. Regarding demand-side policies, pharmaceutical prescription budgets or quotas and monitoring of prescriptions (with potential financial incentives or penalties) are in place in eight and in seven countries respectively. Switching is generally allowed, but is solely the physician’s responsibility. Automatic substitution is not recommended, or even forbidden, in most EU MSs. Prescription conditions or guidelines that apply to biosimilars are established in nearly all surveyed EU MSs. Conclusions: Important heterogeneity in policies on biosimilars was seen between (and even within) selected countries, which may partly explain variations in biosimilar uptake. Supply-side policies targeting price have been reported to limit biosimilar penetration in the long term, despite short-term savings, while demand-side policies are considered to positively impact uptake.
Keywords: biosimilar; policies; pricing; savings; uptake biosimilar; policies; pricing; savings; uptake

Share and Cite

MDPI and ACS Style

Rémuzat, C.; Kapuśniak, A.; Caban, A.; Ionescu, D.; Radière, G.; Mendoza, C.; Toumi, M. Supply-Side and Demand-Side Policies for Biosimilars: An Overview in 10 European Member States. J. Mark. Access Health Policy 2017, 5, 1307315. https://doi.org/10.1080/20016689.2017.1307315

AMA Style

Rémuzat C, Kapuśniak A, Caban A, Ionescu D, Radière G, Mendoza C, Toumi M. Supply-Side and Demand-Side Policies for Biosimilars: An Overview in 10 European Member States. Journal of Market Access & Health Policy. 2017; 5(1):1307315. https://doi.org/10.1080/20016689.2017.1307315

Chicago/Turabian Style

Rémuzat, Cécile, Anna Kapuśniak, Aleksandra Caban, Dan Ionescu, Guerric Radière, Cyril Mendoza, and Mondher Toumi. 2017. "Supply-Side and Demand-Side Policies for Biosimilars: An Overview in 10 European Member States" Journal of Market Access & Health Policy 5, no. 1: 1307315. https://doi.org/10.1080/20016689.2017.1307315

APA Style

Rémuzat, C., Kapuśniak, A., Caban, A., Ionescu, D., Radière, G., Mendoza, C., & Toumi, M. (2017). Supply-Side and Demand-Side Policies for Biosimilars: An Overview in 10 European Member States. Journal of Market Access & Health Policy, 5(1), 1307315. https://doi.org/10.1080/20016689.2017.1307315

Article Metrics

Back to TopTop